Edward L. Schwartz, Ph.D.

Medicine

Phone718-430-8864
Emailedward.schwartz@einsteinmed.org
Websitehttp://www.einstein.yu.edu/faculty/5589/edward-schwartz/

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Edward L. Schwartz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

2 Active
4 Finished

Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53
Zhao, H. & Schwartz, E. L.
National Cancer Institute
4/12/19 → 3/31/22
Project: Research project
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
Schwartz, E. L.
6/3/16 → 5/31/21
Project: Research project
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
Schwartz, E. L., Schwartz, E. L., Rose, S. A. & Rose, S. A.
National Cancer Institute, National Institutes of Health
7/9/12 → 5/31/18
Project: Research project
Anti-angiogenic actions of taxotere
Schwartz, E. L. & Rose, S. A.
National Cancer Institute
9/29/03 → 6/30/09
Project: Research project
Mechanisms of thymidine phosphorylase angiogenesis
Schwartz, E. L. & Rose, S. A.
National Cancer Institute
6/1/01 → 4/30/12
Project: Research project

4346 Citations
31 h-Index
84 Article
5 Review article
2 Letter

Skp2 Depletion Reduces Tumor-Initiating Properties and Promotes Apoptosis in Synovial Sarcoma
Wang, J., Sato, K., O'Donnell, E., Singla, A., Yaguare, S., Aldahamsheh, O., Batko, B., Borjihan, H., Tingling, J., Zhang, J., Weiser, D. A., Loeb, D. M., Gorlick, R., Schwartz, E. L., Yang, R., Zi, X., Zhao, H., Geller, D. S. & Hoang, B. H., Oct 2020, In: Translational Oncology. 13, 10, 100809.
Research output: Contribution to journal › Article › peer-review

Open Access
Targeted inhibition of the E3 ligase SCFSkp2/Cks1 has antitumor activity in RB1-deficient human and mouse small-cell lung cancer
Zhao, H., Iqbal, N. J., Sukrithan, V., Nicholas, C., Xue, Y., Yu, C., Locker, J., Zou, J., Schwartz, E. L. & Zhu, L., Jun 2020, In: Cancer research. 80, 11, p. 2355-2367 13 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Lysosome membrane permeabilization and disruption of the molecular target of rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a chloroquinoline analog
Sironi, J., Aranda, E., Nordstrøm, L. U. & Schwartz, E. L., Jan 2019, In: Molecular Pharmacology. 95, 1, p. 127-138 12 p.
Research output: Contribution to journal › Article › peer-review
9 Scopus citations
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells
Nordstrøm, L. U., Sironi, J., Aranda, E., Maisonet, J., Perez-Soler, R., Wu, P. & Schwartz, E. L., Feb 12 2015, In: ACS Medicinal Chemistry Letters. 6, 2, p. 134-139 6 p.
Research output: Contribution to journal › Article › peer-review
15 Scopus citations
RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., Chachoua, A., Goel, S., Schwartz, E. L., Zhu, C., Shan, J., Yu, Y., Gritsman, K., Yelensky, R., Lipson, D., Otto, G. & 5 others, Hawryluk, M., Stephens, P. J., Miller, V. A., Piperdi, B. & Perez-Soler, R., Dec 2015, In: Cancer discovery. 5, 12, p. 1262-1270 9 p.
Research output: Contribution to journal › Article › peer-review
53 Scopus citations